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Mitochondrial dysfunction has been implicated in the pathophysiology of neurodegenerative disorders, including multiple sclerosis
(MS). To date, the investigation of mitochondrial dysfunction in MS has focused exclusively on neurons, with no studies exploring
whetherdysregulationofmitochondrial bioenergetics and/or genetics in oligodendrocytesmight be associatedwith the etiopathogenesis
ofMS and other demyelinating syndromes. To address this question, we established amousemodel wheremitochondrial DNA (mtDNA)
double-strand breaks (DSBs) were specifically induced in myelinating oligodendrocytes (PLP:mtPstI mice) by expressing a mitochondrial-
targetedendonuclease,mtPstI, startingat3weeksofage. Inboth femaleandmalemice,DSBsofoligodendroglialmtDNAcaused impairmentof
locomotor function, chronic demyelination, glial activation, and axonal degeneration, which became more severe with time of induction. In
addition, after short transient induction of mtDNA DSBs, PLP:mtPstI mice showed an exacerbated response to experimental autoimmune
encephalomyelitis. Together, our data demonstrate thatmtDNAdamage can cause primary oligodendropathy, which in turn triggers demyeli-
nation,provingPLP:mtPstImice tobeauseful tool tostudythepathological consequencesofmitochondrialdysfunction inoligodendrocytes. In
addition, the demyelination and axonal loss displayed by PLP:mtPstI mice recapitulate some of the key features of chronic demyelinating
syndromes, including progressiveMS forms, which are not accurately reproduced in themodels currently available. For this reason, the PLP:
mtPstImouse represents a unique andmuchneeded platform for testing remyelinating therapies.
Key words: animal model; demyelination; mitochondria; multiple sclerosis; oxidative phosphorylation; remyelination
Introduction
Multiple sclerosis (MS) is a chronic demyelinating disorder of the
CNS affecting2.5million individuals worldwide.MSmanifests
in genetically susceptible individuals with environmental factors
influencing penetrance and clinical course.
It is still unclearwhetherMS is caused by a peripheral or aCNS
trigger (Dendrou et al., 2015; Axisa and Hafler, 2016). According
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Significance Statement
In this study, we show that oligodendrocyte-specific mitochondrial DNA double-strand breaks in PLP:mtPstI mice cause oligo-
dendrocyte death and demyelination associated with axonal damage and glial activation. Hence, PLP:mtPstI mice represent a
unique tool to study the pathological consequences ofmitochondrial dysfunction in oligodendrocytes, aswell as an ideal platform
to test remyelinating and neuroprotective agents.
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to the “CNS extrinsic” hypothesis of MS, autoreactive T cells
enter the CNS where they activate the innate immune response
and cause demyelination. This is well suited in modeling the
relapsing–remitting form of MS (Trapp and Nave, 2008; Den-
drou et al., 2015) but alone does not accurately fit the pathophys-
iology of progressive MS where axonal damage, demyelination,
and neurodegeneration are often independent of immune cell
presence. As such, progressiveMS is best described as a syndrome
with some pathological aspects that likely are dependent on au-
toimmune activation from a peripheral trigger, and with others
possibly caused by a CNS-specific trigger. This latter pathological
mechanism is defined in the so-called “CNS intrinsic” model,
where events in theCNS are believed to initiate the disease (Trapp
and Nave, 2008; Dendrou et al., 2015; Mahad et al., 2015). In
support of this hypothesis, oligodendrocyte death and demyeli-
nation have been shown to occur in the absence of T cells, with
demyelinating lesions characterized by axonal transection, and
histopathologically similar to those observed in neurological dis-
orders like stroke (Lucchinetti et al., 2000; Peterson et al., 2001;
Aboul-Enein et al., 2003). This is true in the rodent brain as well,
where primary oligodendrocyte death triggers CNS inflamma-
tion, followed by a T-cell response andmyelin autoantibody pro-
duction (Traka et al., 2016). Still, a better understanding of the
molecular mechanisms underlying neurodegeneration in pro-
gressive MS is needed.
Mitochondrial dysfunction has been implicated in the patho-
physiology of neurological disorders, including MS (Witte et al.,
2014; Cabezas-Opazo et al., 2015; Keogh and Chinnery, 2015;
Ryan et al., 2015; Patergnani et al., 2017). Dysfunctional mito-
chondria contribute to axonal damage and neuronal loss in MS
(Dutta et al., 2006;Mahad et al., 2008;Witte et al., 2014) as well as
experimental autoimmune encephalomyelitis (EAE; Nikic´ et al.,
2011; Sadeghian et al., 2016). It has also been shown that mito-
chondrial DNA (mtDNA) mutations could underlie neuronal
mitochondrial dysfunction inMS (Kalman et al., 1995; Ban et al.,
2008; Andalib et al., 2013). Further evidence pointing at a con-
nection between mitochondrial dysfunction and MS is that de-
myelination occurs in various mitochondrial diseases including
Leber’s hereditary optic neuropathy (LHON; Yu-Wai-Man et al.,
2011), Friedreich’s ataxia (Koeppen and Mazurkiewicz, 2013),
and Charcot-Marie-Tooth disease type 2A (Kwong et al., 2006).
In LHON, which is caused by mtDNA mutations, patients have
increased risk of developing an MS-like syndrome known as
Harding’s disease (Palace, 2009) and display white matter lesions
indistinguishable from those found in MS patients (Matthews et
al., 2015), suggesting that mitochondrial dysfunction could be a
common pathophysiological pathway in these disorders.
To date, the investigation ofmitochondrial dysfunction inMS
has focused only on neurons, partially because oligodendrocytes
have been shown to be highly glycolytic and relatively resistant to
oxidative phosphorylation (OXPHOS) defects (Fu¨nfschilling et
al., 2012). Our hypothesis is that, at least in some MS forms,
primary oligodendropathy caused by mitochondrial damage
and/or dysfunction may result in myelin degradation causing
neuroinflammation and secondary activation of autoreactive T
cells. Using the PLP:mtPstI mouse model, here we show that
mtDNA double-strand breaks (DSBs) cause primary oligoden-
dropathy, which leads to demyelination, axonal injury, and glial
activation. On this basis, we believe an investigation of oligoden-
drocyte-specific mitochondrial dysfunction in MS patients as a
possible contributor toMS pathogenesis is warranted. Finally, we
show that PLP:mtPstI mice serve as a customizable model of
chronic progressive demyelination, and may be used as a plat-
form for testing agents targeting CNS remyelination and repair.
Materials andMethods
Mice
PLP:mtPstI transgenic mice were generated by breeding hemizygous
proteolipid protein (PLP)-tetracycline transactivator (tTA) mice
(Inamura et al., 2012) with hemizygous mitochondrial-PstI (mtPstI)
mice (Fukui and Moraes, 2009), both backcrossed for a minimum
of eight to nine generations to a C57BL/6 background. The genotype
was confirmed with the following primers: PLP-tTA, forward
5-CGGAGTTGATCACCTTGGACTTGT-3, and reverse 5-TTTCCC
ATGGTCTCCCTTGAGCTT-3; and mtPstI, forward 5-GGAGGGGA
AGCTTATGAAG-3, and reverse 5-CCGTTGGGGTAGTTATGCAG-3.
The mito-EYFP [enhanced yellow fluorescent protein; C57BL/6-
Tg(tetO-COX8A/EYFP)1Ksn/J] reporter line (Chandrasekaran et al.,
2006) was obtained from The Jackson Laboratory (catalog #006618) and
genotyped with the following primers: transgenic allele, forward 5-
GCTGACCCTGAAGTTCATCTGC-3, and reverse 5-CATGATATA
GACGTTGTGGCTGT-3; and internal positive control, forward 5-CAA
ATGTTGCTTGTCTGGTG-3, and reverse 5-GTCAGTCGAGTGCAC
AGTTT-3. In all experiments (including the EAE experiment), control
mice were littermates of the PLP:mtPstI transgenic mice, constituting a
mix of WT, PLP-tTA, and mtPstI mice. Transgenic and control mice
were kept on the same doxycycline (DOX) regimen, and given DOX-
containing food (200mg/kg; Bio-Serv) for variable lengths of time (until
weaning age, throughout life, or temporarily) depending on the experi-
ment. Transgenic and controlmice were housed together throughout the
experimentation. Colonies were housed at the Animal Facility of The
Miami Project to Cure Paralysis in a virus-free/antigen-free vivarium
with a 12 h light/dark cycle and controlled temperature and humidity,
and were provided with water and food ad libitum. Mice were group
caged (maximum five per cage) throughout the duration of the experi-
ments. Experiments were performed according to protocols and guide-
lines approved by the Institutional Animal Care and Use Committee of
the University of Miami, and all efforts were made to minimize pain and
distress.
Behavioral assays
Open field test. The open field test was performed in adultmalemice in an
odor-free, nontransparent square arena, as previously described (Mad-
sen et al., 2016b). The arena was divided into three zones (wall, interme-
diate, and center), andmouse behavior was recorded over a 5min period
using a high-resolution video camera. The total number of lines crossed,
the time spent in each zone, and stereotypical behavior such as rearing
were analyzed and expressed as number of events.Mice that did not enter
all three zones or cross aminimumof 50 lines during the 5min trial were
excluded.
Rotarod test. Motor coordination and balance were tested on the ac-
celerating rotarod (10–60 rpm over 10 min period and constant accel-
eration; Rotamex 4/8, Columbus Instruments) using adult male mice.
The test consisted of a 5 d pretraining period (days 1–5) followed by the
actual test (day 7). The total time on the accelerating rod was automati-
cally recorded, and nonwalking behaviors (e.g., passive clinging to the
rod) were manually corrected for. Mice that could not maintain their
balance on the rod for a minimum of 60 s during pretraining were ex-
cluded (Lambertsen et al., 2012).
Induction of EAE with myelin oligodendrocyte glycoprotein
35–55 peptide
Active EAE was induced in adult (2–3 months) female PLP:mtPstI and
control mice using the myelin oligodendrocyte glycoprotein 35–55 pep-
tide (MOG35–55; BioSynthesis) as previously described (Madsen et al.,
2016a). Mice received an intraperitoneal injection of pertussis toxin dis-
solved in PBS (400 ng/mouse; day 0), followed by subcutaneous injection
of MOG35–55 peptide (300 ng/mouse; day 1) emulsified in complete
Freund’s adjuvant (200l total volume), followed by a second intraperi-
toneal injection of pertussis toxin (400 ng/mouse; day 2). The disease
coursewas assessed daily using a standardized scale from0 to 6 as follows:
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0, no clinical signs; 1, loss of tail tone; 2, flaccid tail; 3, complete hindlimb
paralysis; 4, complete forelimb paralysis; 5, moribund; and 6, dead. In-
crements of 0.5 points were applied for intermediate behaviors.
Immunohistochemistry
Mice were transcardially perfused with 0.1 M PBS followed by 4% para-
formaldehyde (PFA) in 0.1 M PBS. Spinal cord, brain, and optic nerve
were dissected out and postfixed in 4% PFA in 0.1 M PBS for 2 h followed
by cryoprotection in 0.1 M PBS plus 20% sucrose. Spinal cord tissue was
cryostat sectioned into 14- or 30-m-thick serial sections. Sections were
blocked with 5% normal goat serum in 0.1 M PBS plus 0.4%Triton-X for
1 h and incubated overnight at 4°C with primary antibodies against GFP
(chicken, 1:1000; Abcam), APC (CC1 clone, mouse, 1:500; Millipore),
Olig2 (rabbit, 1:500; Millipore), Iba1 (rabbit, 1:500; Wako), GFAP (rab-
bit,1:800; Dako), and microtubule associated protein 2 (MAP2; rabbit,
1:500; Millipore). Positive staining was visualized with secondary
species-specific fluorescent antibodies (goat anti-mouse Alexa Fluor 488
and 594, goat anti-rabbit Alexa Fluor 488 and 594, goat anti-chicken
Alexa Fluor488, all diluted 1:750; Invitrogen). Cytochrome c oxidase I
(COX1) was identified with anti-MTCO1-Alexa Fluor 488 antibody
(mouse, 1:500; Abcam). Lastly, sections were stained with DAPI (1:1000;
stock, 1 mg/ml; Invitrogen) for 5 min, coverslipped, and imaged with an
Olympus FluoView 1000 Confocal Microscope or with a Zeiss Axiovert
A1 Fluorescence Microscope.
Quantification of glial cells in the spinal cord
Total Iba1 microglia and Olig2CC1 oligodendrocytes were esti-
mated in the thoracic spinal cord by stereology. Five 30-m-thick serial
sections taken 300mapart were analyzed. Positive cells were counted at
63magnification with a Zeiss Axiovert A1 fluorescence microscope by
a blinded investigator. The total number of positive cells per cubic mil-
limeter was estimated using Stereo Investigator Software (MBF Biosci-
ence) to ensure unbiased counting and systematic random sampling.
GFAP intensity was quantified in the thoracic spinal cord from images
acquired at 10 magnification with identical exposure time, analyzed
using ImageJ after background subtraction, and expressed as intensity
per square micrometer.
Isolation of O4 oligodendrocytes
Mice were transcardially perfused with PBS, and brains and spinal cords
were harvested and dissociated into single-cell suspensions using the
Adult Brain Dissociation Kit (Miltenyi) according to manufacturer pro-
tocols. After red blood cell lysis, cells were resuspended in PBS plus 0.5%
BSA, and oligodendrocytes were isolated by positive selection with O4
magnetic microbeads (Miltenyi) in combination with LS columns
(Miltenyi).
Real time RT-PCR
Total RNA was isolated using the RNeasy Micro Kit (Qiagen) and
cleaned of genomic DNA by on-column DNase digestion. For isolated
oligodendrocytes, 30 ng of RNA was reversed transcribed with Sensis-
cript Reverse Transcriptase Kit (Qiagen), whereas for sciatic nerves 200
ng of RNAwas reversed transcribed with Omniscript Reverse Transcrip-
tase Kit (Qiagen). In parallel, reactions without reverse transcriptase
(no-RT) were set up to estimate possible genomic DNA contamination.
Real-time PCR amplification was performedwith PowerUp SYBRGreen
PCR Master Mix (Invitrogen) in an ABI 7300 Real-Time PCR System
(Thermo Fisher Scientific). COX1 was amplified with 5-AGGCTTCAC
CCTAGATGACACA-3 (forward) and 5-GTAGCGTCGTGGTATTCC
TGAA-3 (reverse) primers; PstI with 5-GATTACAAGCCCAATTC
CC-3 (forward) and 5-ATTGTCCTTGGAGTTGGTG-3 (reverse)
primers; and-actinwith 5-TAGACTTCGAGCAGGAGATGG-3 (for-
ward) and 5-CAAGAAGGAAGGCTGGAAAAGAG-3 (reverse) prim-
ers. Relative gene expression was calculated with the Ct method after
normalization to -actin and subtraction of no-RT expression.
Assessment of mtDNA content and mtDNA deletions
Mice were perfused with cold PBS, and total DNA was isolated from
whole spinal cord homogenates by phenol/chloroform extraction. Genes
were amplified usingMaxima SYBRGreen/ROXqPCRMasterMix (Fer-
mentas) in a CFX96 Realtime PCR system (BIO-RAD). The following
primers were used for amplification: COX1, 5-AGGCTTCACCCTA
GATGACACA-3 (forward) and 5-GTAGCGTCGTGGTATTCCTG
AA-3 (reverse); ND1, 5-CAGCCTGACCCATAGCCATA-3 (forward)
and 5-ATTCTCCTTCTGTCAGGTCGAA-3 (reverse); and genomic
-actin, 5-GCGCAAGTACTCTGTGTGGA-3 (forward) and 5-CAT
CGTACTCCTGCTTGCTG-3 (reverse). COX1 mtDNA content was
calculated with the Ct method after normalization to genomic DNA
content (-actin). Data were corrected for relative PCR amplification
efficiency using BIO-RAD CFX Manager Software (version 3.0). To de-
tect mtDNA deletions, which wemeasured by the occurrence of mtDNA
recombination, primers flanking the following PstI restriction sites were
designed: PstI-8300, 5-TTGCCCACTTCCTTCCACAAG-3; and PstI-
12812, 5-TCGGATGTCTTGTTCGTCTG-3.
Estimation of demyelinated white matter volume
Thoracic spinal cord sections were permeabilized with 0.1 M PBS plus
0.4% Triton-X and stained with FluoroMyelin Red Fluorescent Myelin
Stain (1:400; Invitrogen) for 20 min at room temperature. Sections were
blocked with 5% normal goat serum in 0.1 M PBS plus 0.4%Triton-X for
1 h and colabeled with anti-GFAP as described above. Five 30-m-thick
serial sections taken 300 m apart were used for the assessment. The
entire white matter and the demyelinated areas were traced at 5mag-
nification with a Zeiss Axiovert A1 Fluorescence Microscope. Total and
demyelinated white matter volume were estimated using Neurolucida
Software (MBF Bioscience).
Immunohistochemistry in flat-mounted retinas and quantification
of retinal ganglion cell numbers
Tissues were processed as previously described (Brambilla et al., 2012).
Briefly, eyes were enucleated and immersion fixed in 4%PFA, pH 7.4, for
1 h. Retinas were then removed and cryoprotected overnight in 30%
sucrose. Before staining, retinas were subjected to three freeze–thaw cy-
cles, rinsed in PBS, and blocked for 1 h in 0.1 M Tris buffer containing 5%
donkey serum and 0.1% Triton X-100. After overnight incubation with
Cy3-conjugated anti-NeuN antibody (1:500;Millipore), retinas were flat
mounted, coverslipped, and imaged with a Leica TSL AOBS SP5 Confo-
cal Microscope equipped with Leica LAS AF software. Quantification of
NeuN RGCs was performed with ImageJ by a blinded investigator on
20 images randomly collected from the four retinal quadrants at the
same eccentricity (1–1.5 mm from the optic disk). Retinal GFAP inten-
sity was analyzed using ImageJ after background subtraction and was
expressed as GFAP intensity per square micrometer.
Western blotting
Mice were transcardially perfused with chilled 0.1 M PBS, and the brain
and spinal cord were immediately dissected out and snap frozen in liquid
nitrogen. The cord was split vertically into the two columns. One sample
was homogenized in 300 l of RIPA buffer (with phosphatase inhibitor
cocktail 1, Sigma-Aldrich; and Complete Protease Inhibitor Cocktail,
Roche Diagnostics), and 20 g of proteins were loaded per sample and
run on an 11% SDS-PAGE gel. Proteins were transferred to a 0.2 m
nitrocellulose membrane, and unspecific binding was blocked with 5%
nonfat milk or 5% BSA in TBS-T for 1 h at room temperature. The
membranewas then incubatedwith primary antibodies against PstI (rab-
bit, 1:1000; Moraes laboratory), myelin basic protein (MBP; rat, 1:5000;
Millipore), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
rabbit, 1:2500; Abcam) at 4°C overnight. Proteins were stained with
HRP-conjugated species-specific secondary antibodies (all 1:2000; GE
Healthcare) and visualized with Super Signal West Pico Chemilumines-
cent substrate (Thermo Fisher Scientific). Bands were quantified with
Quantity One software (BIO-RAD). Data were normalized to GAPDH
and expressed as relative protein expression (in arbitrary units) or as a
percentage of 2-month-old control mice.
Toluidine blue analysis and electron microscopy
PFA-fixed 1 mm segments of the thoracic spinal cord were postfixed
overnight in 2% glutaraldehyde plus 100mM sucrose in 0.15 M phosphate
buffer before incubationwith 2%OsO4 for 1 h. Following dehydration in
graded ethanol solutions, tissues were embedded in epoxy resin (Embed,
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Figure 1. Generation and characterization of PLP:mtPstI mice. A, Schematic of the generation of PLP:mtPstI mice. PLP-tTA mice expressing the tTA under the control of the PLP promoter were
crossedwithmice expressing amtPstI downstream of a TRE. In the absence of DOX (DOX) tTA binds to TRE, initiating PstI transcription (tet-off system).B, Diagram ofmouse circular mtDNAwith
PstI restriction sites (8420 and 12,239 nt, blue scissors) and primers (red arrows) for the amplification of recombinedmtDNA fragments generated following PstI cleavage. C, Experimental timeline:
mice receivedDOXuntil P21andwere sacrificed at 2, 4, or 6months of age.D, PstI protein expression in the spinal cords of 2-, 4-, and6-month-oldPLP:mtPstI (mtP) and control (c)mice; recombinant
PstI was included as positive control. E, Real-time PCR quantification of COX1 in the spinal cord of 2-, 4-, and 6-month-oldmice as ameasure ofmtDNA depletion. Results are normalized to genomic
-actin and are expressed as percentage of 2-month-old controls; n 3–7/group; *t(4) 3.031, p 0.0387, t test. F, Real-time PCR quantification of recombinedmtDNA in PLP:mtPstI mice as
ameasure ofmtDNA deletions; n 4–5/group; *t(7) 2.407, p 0.047, t test. AU, Arbitrary units.G, Real-time PCR quantification of COX1 gene expression in oligodendrocytes from spinal cords
and brains of 4-month-old control and PLP:mtPstI mice; n 3–4/group; *t(4) 4.259, p 0.0131, t test; **t(6) 5.131, p 0.0022, t test.H, Confocal images of the spinal cord white matter
of 2M control and PLP:mtPstI mice colabeled with CC1 and mitochondrial COX1; white arrows show localization of COX1 in CC1mature oligodendrocytes. Scale bars, 10m. I, Representative
confocal images from the thoracic spinal cords of 2-month-old PLP:mitoEYFP mice after 5 weeks of reporter induction (EYFP). Sections were colabeled for CC1, GFAP, Iba1 and MAP2. Scale bar,
10 m. J, Progressive phenotypic changes in PLP:mtPstI mice induced at P21 compared with control mice. K, Assessment of body weight in PLP:mtPstI mice (Figure legend continues.)
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ElectronMicroscopy Sciences). Semithin (1-m-thick) sectionswere cut
using a Leica Ultracut E Microtome and were stained with 1% toluidine
blue solution. Samples were then examined by light microscopy. The
number of toluidine blue-stained myelinated or degenerated axons as
well as infiltrating cells were estimated using the Stereo Investigator Soft-
ware (MBF Bioscience). From the same specimens, ultrathin sections
(60–90 nm thick) were cut for electron microscopy (EM) and imaged
with a Philips CM10 Transmission Electron Microscope.
Quantification of axon diameter/fiber diameter ratios and
assessment of remyelinating axons
For evaluating the g-ratio (axon diameter/fiber diameter ratio) of axons
in the thoracic spinal cord, EMmicrographs were acquired at 5.2K mag-
nification using the Philips CM10 Transmission Electron Microscope
(Brambilla et al., 2011). A grid was placed over the entire spinal cord
section, and one picture was acquired randomly from each quadrant of
both white and gray matter. For each animal, a minimum of 25 images
was analyzed.On eachmicrograph, the fiber diameter and axon diameter
of each single axon were measured using ImageJ software. Due to the
irregular shapes of the elements, the approximate diameter was calcu-
lated as the average of two diameters measured for each element.
Cell isolation for flow cytometry
Following transcardial perfusionwith PBS, spinal cords and spleens were
harvested andplaced in coldHBSS (withMg2 andCa2). Sampleswere
mechanically dissociated into single-cell suspensions through a 70 m
cell strainer and washed in HBSS. The spleen samples were spun at 400 g
for 5 min, supernatant was removed, and red blood cells were lysed in
2ml of lysis buffer (eBioscience) according tomanufacturer instructions.
Cells were then resuspended in flow cytometry buffer (FCB, eBioscience)
and stained as described below. Leukocytes infiltrating into the spinal
cord were isolated by negative selection of single-cell spinal cord suspen-
sions with Myelin Removal Beads II using the LS magnetic columns as de-
scribed in themanufacturer protocol (Miltenyi). Similar to the splenocytes,
spinal cord cells were resuspended in FCB and stained as described below.
The number of viable cells was determined by Trypan Blue exclusion assay
using the TC20 Automated Cell Counter (BIO-RAD).
Immunolabeling and flow cytometric analysis
Cells were resuspended in 100 l of FCB, blocked with 2 l of TruStain-
FcX (anti-mouse CD16/32 FcR block, BioLegend) for 10min at 4°C, and
stained for 30 min at 4°C with the following antibodies: APC-Cy7-anti-
CD45 (1:200; BioLegend), FITC-anti-CD4 (1:200; eBioscience), PerCP-
Cy5.5-anti-CD8a (1:200; eBioscience), PE-Cy7-anti-CD25 (1:200;
eBioscience), PE-anti-CD45R/B220 (1:200; BioLegend), and eFluor450-
anti-CD11b (1:200; eBioscience). Cell suspensions were then fixed in 1%
PFA for 1 h and, finally, resuspended in 500 l of FCB. Samples were
analyzed with an LSRII Flow Cytometer (BD Biosciences) equipped with
FACS-Diva 6.0 Software (BD Biosciences).
Anti-MOG and anti-PLP antibody detection
Blood samples were collected directly from the heart before transcardial
perfusion with PBS or PFA. The blood was allowed to coagulate for
30 min at room temperature, and serum was isolated by centrifugation
for 10 min at 10,000 rpm. Serum samples were diluted 1:2 and analyzed
for the presence of antibodies (IgGs) against MOG and PLP. Preblocked
ELISA plates coated with recombinant mouse MOG1–125 (AnaSpec) or
PLP178–191 (AnaSpec) peptides were used for detection. The assay was
performed in duplicate and according to the manufacturer protocol.
Briefly, 100 l of serum were loaded into each well and incubated for
30 min at room temperature. Wells were washed and incubated with
peroxidase-conjugated antibodies against mouse IgG for 1 h at room
temperature. The reaction was developed by adding 50 l of tetrameth-
ylbenzidine to each well, and the optical density was measured at 450 
using a spectrophotometer. The relative anti-MOG and anti-PLP IgG
concentrations were estimated based on the manufacturer-provided
standard and expressed as nanograms per milliliter.
Experimental design and statistical analysis
All statistical analyses were conducted with GraphPad Prism 5. Statistical
tests and specific parameters are detailed in each individual figure legend.
Female mice were used for all experiments unless otherwise specified,
and no sex differences were observed in the PLP:mtPstI mouse with
respect to PstI expression, behavior, or histopathological outcome.
In Figure 1, the data are reported as follows: Figure 1E, n 3–7/group,
Student’s t test between 6-month-old control and PLP:mtPstI mice; Fig-
ure 1F, n  3–5/group, Student’s t test between 2- and 4-month-old
PLP:mtPstI mice; Figure 1G, n  3–4/group, Student’s t test between
control and PLP:mtPstI mice; and Figure 1K, the weight was recorded in
malemice, n 3–7/group, Student’s t test between genotypes at individ-
ual time points.
In Figure 2A–F, all behavioral assessments were conducted usingmale
mice. The data for Figure 2 are reported as follows: Figure 2A, n 
4–9/group, statistical comparison between groups or genotypic diff-
erences over time were assessed with a one-way ANOVA followed by
Bonferroni’s multiple-comparison test; Figure 2B,C, n  4–12/group,
one-way ANOVA followed by Bonferroni’s multiple-comparison test to
compare over time, and Student’s t test to compare matching time
points; Figure 2G, n  3–4/group, Student’s t test between control and
PLP:mtPstI mice at each time point; Figure 2H, n  3–6/group, Stu-
dent’s t test between control and PLP:mtPstI mice at each time point;
Figure 2K,M, data were fitted to a linear regression, and slopes and
intersections were compared; Figure 2L,N, Student’s t test between con-
trol and PLP:mtPstImice; and Figure 2P, Student’s t test between control
and PLP:mtPstI mice at each time point.
In Figure 3, the data are reported as follows: Figure 3B, n 3/group,
Student’s t test was applied between genotypes, and one-way ANOVA
followed by Bonferroni’smultiple-comparison test was used for compar-
isons over time; Figure 3C, n  3–4/group, Student’s t test between
genotypes at each time point; Figure 3E,n 5/group, Student’s t test; and
Figure 3G, n 3/group, Student’s t test between genotypes at each time
point.
The data in Figure 4 are reported as follows: Figure 4B, n 4–5/group,
Student’s t test between genotypes at each time point; Figure 4C, n 
7/group, Student’s t test between genotypes at each time point; and Fig-
ure 4E, n 3–5, Student’s t test between genotypes at each time point.
In Figure 5, data are reported as follows: Figure 5B,D, data were fitted
to a linear regression, and slopes and intersection were compared; Figure
5C,E, Student’s t test between control and PLP:mtPstI mice; and Figure
5F–I, n 3/group, Student’s t test between control and PLP:mtPstI mice
at each time point.
In Figure 6, the data are reported as follows: Figure 6E, n  3/group,
Student’s t test; and Figure 6 I,K,L, n 4–5/group, Student’s t test.
Results
Generation and characterization of PLP:mtPstI mice
To investigate the effect of mtDNA damage on oligodendrocyte
function we bred PLP-tTA mice expressing the tTA under the
control of the oligodendrocyte-specific PLP promoter (Inamura
et al., 2012) to tetracycline responsive element (TRE)-mtPstI mice
expressing the endonuclease PstI inmitochondria (mtPstI; Fukui
and Moraes, 2009). In the resulting PLP:mtPstI mice, the PstI
gene, cloned downstream of a mitochondrial targeting sequence,
is inducibly transcribed upon DOX removal and the protein
product is localized to mitochondria (Fig. 1A). Since mouse
mtDNA contains two PstI restriction sites (Fig. 1B), PstI expres-
sion results in mtDNA DSBs. Although some of the cleaved
mtDNA is recombined into shorter mtDNAs, deleting the region
between the PstI sites, the majority of the cleaved molecules is
4
(Figure legend continued.) induced at P21 and in control mice; **t(10) 3.319, n 5–7, p
0.0078, t test; ##t(5) 4.145, n 3–4, p 0.009, t test; ^^t(10) 4.134, n 4–8, p
0.002, t test; ^F(2,10) 7.586, p 0.0099, ANOVA, Bonferroni’s multiple-comparison test: 2-
vs 6-month-old PLP:mtPstImice, t 3.188, p	 0.05; and 4- vs 6-month-old PLP:mtPstImice,
t 3.582, p	 0.05. L, Representative Western blot of PstI expression in non-neural tissues.
M, Month.
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Figure 2. Sustained mtDNA DBSs in oligodendrocytes correlates with worsening of the locomotor phenotype, oligodendrocyte loss, demyelination, and axonal damage in the spinal cord.
A, Balance andmotor coordination evaluatedwith the rotarod test and expressed as time spent on the rod; n 4–9/group; F(5,36) 13.52, p	 0.0001, ANOVA, Bonferroni’smultiple-comparison
test: *t 3.610, p	 0.05; ***t 5.874, p	 0.001;^^t 3.625, p	 0.01;^^^t 6.681, p	 0.001.B–F, Spontaneous activity and anxiety-like behaviors assessedwith the open field test
by measuring the number of lines crossed (B; *F(2,20) 4.692, p 0.0213, ANOVA, Bonferroni’s multiple-comparison test: *t 3.063, p	 0.05; ^t(10) 2.358, p 0.0401, t test; ^^t(6)
5.131, p 0.0022, t test); rearings (C; F(3,20) 16.47, p	 0.0001, ANOVA, Bonferroni’s multiple-comparison test: *t 3.470, p	 0.05; ^t 2.492, p	 0.05; ^^t 4.052, p	 0.01); time
spent in wall (D); interzone (E); and center zone (F); n 4–12/group. G, Stereological quantification of CC1Olig2 oligodendrocytes in the thoracic spinal cord of control and PLP:mtPstI mice;
n 3–4/group, *t(5) 3.120, n 3–4, p 0.0262, t test; **t(4) 5.284, n 3, p 0.0062, t test. H, Quantification of MBP protein expression in the spinal cord; results are normalized to
GAPDHandexpressedas thepercentageof 2-month-old controls;n3–10/group, **t(14)3.334,n6–10,p0.0049, t test. I, RepresentativeMPBWesternblots. C, Control;mtP, PLP:mtPstI.
J, Representative electronmicrographs of the thoracic spinal cord lateral columns of control and PLP:mtPstI mice. Red arrows, Thinly myelinated or demyelinated axons; blue arrows, degenerated
axons. Scale bars, 1m.K,M, Assessmentof theg-ratio at 2 (K) and6 (M)months; valueswereplotted versus the correspondingaxondiameter. Datawere fitted to a linear regression, and the slopes
were significantly different between genotypes. Slopes: 2-month-old control (0.0408
 0.0053, r 2 0.060) vs 2-month-old PLP:mtPstI mice (0.0567
 0.0047, r 2 0.1417). *p 0.027;
6-month-old control (0.0086
 0.0071, r 2 0.0029) vs 6-month-old PLP:mtPstI mice (0.0077
 0.0081, r 2 0.2474). L, N, Quantification of the g-ratio at 2 (L) and 6 (N) months grouped by
increasing axon diameter; L: *t(218) 2.175, p 0.031; #t(974) 6.011, p 0.0004, t test; ****t(388) 4.814, p	 0.0001; ^t(118) 3.122, p 0.002; **t(218) 2.175, p 0.031, t test;
N: #t(183)6.347,p	0.0001;^t(61)7.486,p	0.0001; ****t(41)7.159,p	0.0001, t test.O, Toluidineblue stainingof semithin thoracic spinal cord sections of control andPLP:mtPstImice.
Red arrows, Degenerated collapsed axons. Scale bars, 5m. P, Q, Stereological quantification of myelinated (P) and collapsed (Q) axons in the spinal cord white matter of control and PLP:mtPstI
mice; n 3/group, *t(2) 4.540, n 3, p 0.0452, t test. M, Month, n.d., not determined.
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Figure 3. Sustained mtDNA DBSs in oligodendrocytes lead to astrocyte and microglia activation. A, Representative confocal images of GFAP astrocytes and Iba1microglia in the thoracic
spinal cord white matter of control and PLP:mtPstI mice. Scale bar, 10m. B, Quantification of GFAP fluorescence intensity in the spinal cord thoracic segment as a measure of astrogliosis; n
3/group. *t(4) 2.893, n 3, p 0.0444, t test; ***t(4) 17.62, n 3, p	 0.0001, t test;
###F(3,8) 195.5, p	 0.0001, ANOVA, Bonferroni’smultiple-comparison test: t 18.37, p	 0.001.
C, Stereological quantification of Iba1 cells in the spinal cord; n 3–4/group. **t(3) 7.207, n 3, p 0.0055, t test; ##t(5) 5.897, n 3–4, p 0.0020, t test. D, Representative flow
cytometry plots of CD45CD11b microglia in the spinal cord of control and PLP:mtPstI mice at 2 months showing population frequency and CD45 mean fluorescence intensity (MFI).
E, Quantification of the CD45 MFI; n 5/group. **t(8) 3.805, n 5, p 0.0052, t test. F, Toluidine blue staining of semithin thoracic spinal cord sections from control and PLP:mtPstI mice at
6 months. Red arrows show infiltrating immune cells. Scale bars, 5m. G, Quantification of infiltrating immune cells in the spinal cord white matter of control and PLP:mtPstI mice; n 3/group.
**t(2) 10.68, p 0.0086, t test. M, Month.
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Figure 4. Sustained mtDNA DBSs in oligodendrocytes induce tissue damage in optic nerve and retina. A, Representative electron micrographs of the optic nerve of 6-month-old control and
PLP:mtPstI mice. Red arrows indicate remyelinated axons and blue arrows bare demyelinated axons. Scale bars, 2m.B, C, Quantification of NeuN RGCs in the retina of 2-month-old control and
PLP:mtPstImice (B;WR,whole retina; C, center retina; I, intermediate retina; P, peripheral retina.*t(7)3.484,n4–5,p0.0102, t test;**t(7)4.794,n4–5,p0.0020, t test;##t(7)3.544,
n 4–5, p 0.0094, t test;^^t(7) 4.295, n 4–5, p 0.0036, t test) and of 6-month-old control and PLP:mtPstImice (C; ***t(12) 6.063, n 7, p	 0.0001, t test; ###t(12) 5.087, n
7, p 0.0003, t test).D, Representative confocal images of flatmounted retinas of control and PLP:mtPstImice showingNeuN and GFAP cells in the center,middle, and peripheral zones of the
retina. Scale bars, 100m. E, Quantification of GFAP fluorescence intensity in the retina expressed as a percentage of the corresponding control (*t(5) 3.176, n 3–4, p 0.0247, t test;
**t(7) 5.056, n 4–5, p 0.0015, t test). M, Month.
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degraded, leading to mtDNA depletion (Fukui and Moraes,
2009). We assessed mtDNA damage in mice deprived of DOX at
postnatal day 21 (P21) and sacrificed at 2, 4, and 6 months of age
(Fig. 1C).Western blot analysis of the spinal cord showed a time-
dependent increase of mtPstI in PLP:mtPstI mice and no
expression in control littermates (Fig. 1D). This resulted in
reduced mtDNA levels at 6 months (Fig. 1E) and in the presence
of mtDNA deletions (Fig. 1F). PstI-dependent mtDNA DSBs
caused reduced expression of mtDNA-coded COX1 in oligoden-
drocytes isolated from spinal cord and brain (Fig. 1G). This re-
sulted in a reduced COX1 protein level in oligodendrocytes, with
diminished COX1 immunoreactivity in PLP:mtPstI mice already
evident at 2months (Fig. 1H, white arrows). COX1 is an essential
component of complex IV of the mitochondrial electron trans-
port chain, and low steady-state levels have been associated with
OXPHOS dysfunction (Diaz et al., 2005).
To confirm the specificity of mtPstI expression in oligo-
dendrocytes, we crossed our PLP-tTAmice with TRE-mtEYFP
reporter mice (Chandrasekaran et al., 2006). Five weeks after
induction (age 2 months), EYFP was localized only to CC1
oligodendrocytes, not Iba1 microglia, GFAP astrocytes, or
MAP2 neurons (Fig. 1I), confirming previous observations
(Inamura et al., 2012) that this PLP-tTA mouse line drives gene
expression specifically to mature oligodendrocytes. mtPstI ex-
pression led to a reduction in body size and mass (Fig. 1 J,K),
accompanied by hair graying. As this could indicate mtPstI ex-
pression outside the nervous system, we measured mtPstI by
Western blot in various non-neural tissues but found no signal in
any of the organs tested (Fig. 1L).
SustainedmtDNADSBs in oligodendrocytes correlate with
worsening of the locomotor phenotype
Assessment of motor coordination with the rotarod test in mice
induced at P21 showed that PLP:mtPstI mice performed worse
than controls at 4 months and deteriorated further at 6 months
(Fig. 2A). PLP:mtPstI mice also displayed progressive reduction
of spontaneous activitymeasuredwith the open field test (Fig. 2B,
Movie 1, mouse with red tail mark, 4 months of age). This was
accompanied by gait alterations, trunk instability, and loss of tail
tone, leading to a stiff and wobbly walking behavior (Movie 1).
Stereotypical behavior was altered as well, with a reduction in the
number of rearings (Fig. 2C), likely due to a lack of weight sup-
port by the hindlimbs (Movie 1). Anxiety-related behaviors,
Figure 5. mtPstI expression in the peripheral nervous system does not affect peripheral myelination. A, Representative electron micrographs of the sciatic nerve of 2- and 6-month-old control
and PLP:mtPstI mice. Scale bars, 2m. B, D, Assessment of the g-ratio at 2 (B) and 6 (D) months; values were plotted vs the corresponding axon diameter. Data were fitted to a linear regression,
and the slopeswere not significantly different between genotypes. Slopes: 2-month-old controls (0.0070
 0.0029, r 2 0.026) vs 2-month-old PLP:mtPstImice (0.0055
 0.0029, r 2 0.0160);
6-month-old controls (0.0087
 0.0021, r 2 0.074) vs 6-month-old PLP:mtPstI mice (0.0070
 0.0018, r 2 0.0684). C, E, G-ratio of myelinated fibers at 2 (C) and 6 (E) months grouped by
increasing axon diameter. *t(90) 2.317, p 0.023, t test. F, Real-time PCR quantification of ND1 in the sciatic nerve of 2- and 6-month-old mice as a measure of mtDNA depletion. Results are
normalized to genomic-actin and expressed as the percentage of 2-month-old controls.G, Real-time PCR quantification of recombinedmtDNA in the sciatic nerve asmeasure ofmtDNAdeletions.
H, Real-time RT-PCR quantification ofmtPstI gene expression in the sciatic nerve. I, Real time RT-PCR quantification of COX1 gene expression in the sciatic nerve. AU, Arbitrary units; M,month; n.d.,
nondetectable.
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measured as time spent in each region of the open field, were not
altered (Fig. 2D–F).
SustainedmtDNADSBs in oligodendrocytes correlate with
oligodendrocyte loss, demyelination, and axonal damage in
the spinal cord
Since mtDNA DSBs can lead to cell death (Pickrell et al., 2011),
we investigated whether mtPstI-dependent DSBs of mtDNA
resulted in oligodendrocyte loss. In the spinal cord, the number
of CC1Olig2 oligodendrocytes was reduced in PLP:mtPstI
mice beginning at 2 months (Fig. 2G). This was paralleled by a
reduction in MBP content (Fig. 2H, I). EM analysis showed my-
elin abnormalities, with thinly myelinated or fully demyelinated
axons (Fig. 2J, red arrows). Myelin thickness, quantified by mea-
suring the g-ratio, was mildly but significantly reduced already at
2 months, and most severely at 6 months (Fig. 2K,M), as shown
by the increase in g-ratio. This was also evident as g-ratios were
plotted versus axons grouped by diameter size (Fig. 2L,N). Such
thinning could be due to oligodendrocyte death, and, in some
cases, it might be the sign of axons undergoing spontaneous
remyelination. At 6 months, delayed axonal degeneration was
prominent, likely caused by the loss of myelin support (Fig. 2J,
blue arrows). Indeed, intact and degenerated axons were not
different from control mice at 2 months, but were higher at
6 months (Fig. 2M–P). At this time, axonal damage was so severe
that a reliable identification and quantification of axons with
intact myelin was not possible (Fig. 2N). It should be noted that
at 2months we did not find axonal damage or observe any shift in
the distribution of axonal diameters. At 6 months, however, we
observed a drop in the frequency ofmid-size axons in PLP:mtPstI
mice. This may simply depend on the fact that these axons are by
far the most numerous, hence the probability increases that they
Figure 6. Brief transient induction ofmtDNADSBs in oligodendrocytes leads to the production ofmyelin autoantibodies and a biphasic EAE response.A, Experimental setup: DOXwaswithdrawn
for 3weeks, fromweek5 toweek8, and resumed2dbefore EAE induction. Allmice, both transgenics and controls,were subjected to the same regimen. Controlswere littermates of PLP:mtPstImice,
constituting amix ofWT, PLP-tTA, andmtPstImice.B,Westernblot assessment of PstI protein expression in the spinal cord at 8weeks, immediately after 3weeks ofDOXwithdrawal. C, Controlmice;
mtP, PLP:mtPstImice. Recombinant PstI was included as a positive control. C, Real-time PCR quantification of recombinedmtDNA in PLP:mtPstImice as ameasure ofmtDNAdeletion. n 3/group.
D, Real-time PCR quantification of the mitochondrial-specific genes COX1 and ND1 in the spinal cords of PLP:mtPstI and control mice at 8 weeks as a measure of mtDNA depletion. Results are
normalized togenomic-actin andexpressed as apercentageof the corresponding control;n3/group.E,F, ELISAdetectionof anti-MOG (E; *t(4)4.183,n3,p0.0139, t test) andanti-PLP
(F) antibodies in the serum of PLP:mtPstI and control mice at 8 weeks. G, Clinical course of MOG35–55-induced EAE. Results are expressed as daily mean scores
 SEM of 8–12 mice from 3 independent
experiments. The subacute to chronic phase of the disease (20–40 dpi, starting from peak disease) in PLP:mtPstI mice is significantly different from that in controls; ***p	 0.001, Mann–Whitney test.H,
Representativeconfocal imagesof the thoracic spinal cord labeledwithanti-GFAP(green)andFluroMyelin (red).Scalebars,400m. I, Stereologicalestimationof thedemyelinatedwhitemattervolumebased
onFluroMyelinstaining.Resultsareexpressedasapercentageof totalwhitematter;*t(7)3.168,n4–5,p0.0157, t test. J, Toluidinebluestainingofsemithinthoracic spinal cordsections.Greenarrows,
collapsed axons; red arrows, infiltrating immune cells. Scale bars, 5m.K, L, Stereological estimationof collapsed axons (K; *t(7)2.362,n4–5,p0.0502, t test) and infiltrating cells (L; *t(7)3.105,
n 4–5, p 0.0172, t test) in the spinal cordwhitematter. AU, Arbitrary units; n.d., nondetectable;W,week; dpi, days post induction;WM,whitematter.
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are the target of degeneration. Nevertheless, we cannot exclude
the possibility that some undergo swelling as a result of cellular
stress and consequently shift to a higher diameter size, increasing
the g-ratio measurement.
Collectively, these data demonstrate that mtDNA DSBs are
sufficient to cause primary oligodendropathy, leading to cell
death, demyelination, and axonal damage.
Oligodendropathy in PLP:mtPstI mice induces
glial activation
Injury to the CNS initiates glia-driven inflammation, which con-
tributes to propagating and exacerbating damage (Amor et al.,
2014). Since mtDNA DSBs caused oligo-
dendrocyte loss and accumulation of tis-
sue damage, we investigated whether this
triggered CNS inflammation by assessing
astroglial and microglial responses (Fig.
3A). Astrogliosis, measured by GFAP ex-
pression, was increased in PLP:mtPstI
mice, especially at 6 months (Fig. 3B).
Similarly, at 2 and 6 months PLP:mtPstI
mice showed microgliosis with higher
numbers of Iba1 microglia in the spinal
cord (Fig. 3C) and elevated microglial ex-
pression of CD45, which is suggestive of
increased activation (Fig. 3D,E). At 6
months, we also observed the presence of
peripheral immune cells in the spinal cords
of PLP:mtPstImice,whichwasnot found in
WTmice (Fig. 3F, red arrows,G).
These data show that primary oligoden-
dropathy caused by mtDNA DSBs induces
CNS inflammation driven by resident glial
cells, which is the likely cause of secondary
recruitment of peripheral immune cells to
the CNS.
SustainedmtDNADSBs in
oligodendrocytes induce tissue damage
in the optic nerve and retina
To determine whether tissue damage due
to mtDNA DSBs in oligodendrocytes oc-
curred in other CNS regions, we evaluated
myelin and axon integrity in the optic
nerve, a highly affected area in MS. EM
analysis showed demyelination and ax-
onal loss in PLP:mtPstI mice induced
from P21, most evident at 6 months (Fig.
4A). Axons possibly undergoing remyeli-
nation with thin and highly compact my-
elin could also be found (Fig. 4A, red
arrows). Optic nerve degeneration was
paralleled by pathological changes in the
retina. Indeed, the number of NeuN RGCs
was already reduced at 2 months in PLP:
mtPstI mice in all regions of the retina
(Fig. 4B–D). At 6 months, RGC loss in-
creased further in the central and interme-
diate regions and was virtually complete in
the peripheral region, where tissue dam-
age was so extensive that cells could not be
counted (Fig. 4C,D). RGC death was ac-
companied by astrogliosis, which was
measured by increased GFAP fluorescence (Fig. 4D,E).
mtPstI expression in the peripheral nervous system does not
affect peripheral myelination
The PLP-driven tTA transgene has been found to be expressed in
Schwann cells (SCs; Inamura et al., 2012). This was expected
based on previous reports showing the expression of PLP in this
cell population (Puckett et al., 1987). Hence, to determine whether
in PLP:mtPstImice Schwann cell expression ofmtPstI could alter
peripheral myelin integrity, we assessed myelin thickness/com-
paction by measuring the g-ratio in the sciatic nerve (Fig. 5A–E).
DespitemtPstI being expressed at appreciable levels (even though
Movie1. Video showing theabnormalmotor phenotypeof PLP:mtPstImice (red tag) at 4months (DSBs
induced at 3 weeks), compared to aged-matched controls.
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lower than in the CNS; Fig. 5H), no differences were found be-
tween PLP:mtPstI mice induced from P21 and corresponding
controls both at 2 and 6 months of age (Fig. 5B–E). Morpholog-
ically, no abnormalities were observed (Fig. 5A). To determine
whether mtPstI effectively caused mtDNA DSBs, we quantified
by real-time PCR the mitochondrial-specific gene ND1 as an
index of mtDNA depletion (Fig. 5F) and the presence of recom-
bined mtDNA as an index of mtDNA deletions (Fig. 5G). We
measured a minimal presence of mtDNA deletions (Fig. 5G) and
no mtDNA depletion (Fig. 5F) even at 6 months, indicating the
mtPstI produced only causes minimal mtDNADSBs. The lack of
mtDNA depletion translated into normal expression of mito-
chondrial-specific genes, as shown by COX1 quantification,
which we found unchanged compared with controls (Fig. 5I).
This suggests that OXPHOS is unaffected and can help explain
why we did not measure any alterations in myelin integrity (Fig.
5A–E), indicating that SC survival is not compromised in our
model.
Brief transient induction ofmtDNADSBs in oligodendrocytes
leads to production ofmyelin-specific antibodies
To determine whether even limited damage to mtDNA was
sufficient to cause cellular distress in oligodendrocytes and in-
crease CNS vulnerability to demyelinating injury, we induced
brief transient expression of mtPstI in oligodendrocytes by DOX
deprivation for only 3 weeks, starting at 5 weeks of age (Fig. 6A).
At 8 weeks, as mice were restored to a DOX diet, we assessed
mtPstI protein expression in the spinal cord and detected it in
PLP:mtPstI mice but not in controls (Fig. 6B). Low levels of
mtDNA deletions could be observed by the presence of PCR-
detectable recombinedmtDNA inPLP:mtPstImice (Fig. 6C), but
not by changes in mtDNA content (Fig. 6D). This brief mtPstI
induction led to the production of myelin-specifc antibodies, as
anti-MOG and anti-PLP IgGs were detectable in the serum of
PLP:mtPstI mice (Fig. 6E,F). These data indicate that brief tran-
sient mtDNA DSBs can cause oligodendrocyte distress sufficient
to induce an immune response.
Brief transient induction of mtDNADSBs in
oligodendrocytes leads to exacerbation of chronic EAE
To test whether a relatively brief induction of mtDNA DSBs in
oligodendrocytes altered the CNS response to injury, we induced
EAE in mice deprived of DOX for 3 weeks and 2 d after being
restored to aDOXdiet (Fig. 6A). PLP:mtPstImice showed a delay
in reaching the peak EAE score (Fig. 6G; Table 1). Despite such a
delay, the peak disease phenotype in PLP:mtPstI mice was more
pronounced than in controls (Fig. 6G, Table 1), and peak EAE
scores were sustained chronically with significant disease exacer-
bation comparedwith controlmice. The increase in clinical score
of 0.5 displayed by PLP:mtPstI mice in the chronic phase of
EAE has important functional implications. Controls, with an
average chronic score of 	3, retained full forelimb movement
and only had partial hindlimb paralysis, whereas PLP:mtPstI
mice, with an average chronic score of3.5, had significant im-
pairment of forelimb function in addition to complete hindlimb
paralysis. This was associated with a higher degree of demyelina-
tion (Fig. 6H, I), more severe axonal loss (Fig. 6 J,K), and a sig-
nificant increase in immune cell infiltration (Fig. 6 J,L) into the
spinal cord.
Discussion
Mitochondrial dysfunction has been implicated in MS patho-
physiology. To date, studies in postmortem MS tissues and pre-
clinical models have focused exclusively on neurons, showing
that defective mitochondria contribute to axonal degeneration
and neuronal loss, participating in disease progression and irre-
versible functional impairment (Dutta et al., 2006; Mahad et al.,
2008; Nikic´ et al., 2011;Witte et al., 2014). Despite demyelination
being one of the primary pathological features of MS, whether
mitochondrial dysfunction in oligodendrocytes might play a role
in disease etiology and progression has never been investigated.
This is surprising considering that pattern III MS lesions have
been associated with defects in complex IV of the mitochondrial
respiratory chain not only in axons, but also in oligodendrocytes
(Mahad et al., 2008).
To address this void, we generated the PLP:mtPstImousemodel
where mtDNA DSBs can be timely and reversibly induced by con-
trolling the expression of the mtPstI endonuclease. This is an excel-
lent tool to help us understand how much oligodendrocyte rely on
mtDNA integrity and OXPHOS for survival and to carry out their
physiological functions. By continuous mtPstI induction, we
showed that mtDNADSBs caused oligodendrocyte loss, demyeli-
nation, and axonal injury. These are features characteristically
found in chronic demyelinating disorders, including progressive
MS forms, and are recapitulated by the PLP:mtPstI mouse more
closely than by any in vivo model currently available (e.g., EAE
and cuprizone).
Since mtDNA encodes 13 key proteins of the OXPHOS system,
alterations to mtDNA cause impairment of respiratory function,
compromising themain energyproductionmechanismandcausing
cell death (Pinto and Moraes, 2015). Even though we could not
directly measure OXPHOS in our model because of the low per-
centage of oligodendrocytes in a mixed cell population, we did
observe reducedoligodendroglialCOX1.Arecent reportbyWanget
al. (2016) in which the mitochondrialm-AAA protease coded by
theAfg3l2 gene was deleted in oligodendrocytes supports the idea
that OXPHOS is important for oligodendrocyte survival, even if
they are mainly glycolytic cells that are relatively resistant to
OXPHOS defects (Fu¨nfschilling et al., 2012). Although no leak-
age of mtPstI in the nucleus was observed in our model (Pinto et
al., 2017), the study by Wang et al. (2016) further minimizes
concerns that small amounts ofmtPstI could leak into thenucleus,
as the phenotype they observed by altering a mitochondrial pro-
tease was remarkably similar to the one in our model where
mtDNA was cleaved.
A defect inOXPHOS is also themechanism proposed to cause
cuprizone-induced oligodendrocyte death, as decreased activity
of respiratory chain complexes was found in mitochondria of
cuprizone-treated oligodendrocytes (Pasquini et al., 2007). Fur-
thermore, in vitro exposure of differentiated oligodendrocytes to
complex IV inhibitors caused apoptotic cell death (Ziabreva et
al., 2010). Notably, the small population of surviving oligoden-
drocytes consisted mostly of undifferentiated cells that did not
exhibit overt alterations, suggesting a higher vulnerability of ma-
ture oligodendrocytes to OXPHOS impairment (Ziabreva et al.,
2010).
Table 1. EAE parameters in controls versus PLP:mtPstI mice after brief and
transient induction of mtDNA DSBs















aOnset is considered as the day after the first disease manifestation; CDI Cumulative Disease Index; n 8–13/
group.
*t(19) 3.582, p 0.0020, t test; **t(18) 2.584, p 0.0187, t test.
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A report by Fu¨nfschilling et al. (2012) showed that postmyeli-
nation oligodendrocytes are not as dependent on OXPHOS for
survival as other cells, including nonmyelinating oligodendro-
cytes in vitro, since cytochrome oxidase defects did not cause
oligodendrocyte death or demyelination in mice. They convinc-
ingly showed that myelinating oligodendrocytes survived by
relying on glycolysis, which provided the energy supply in the
absence of functional OXPHOS. In contrast, we did observe a
progressive death ofmyelinating oligodendrocytes that paralleled
the increased accumulation of mtDNA damage and depletion.
This suggests that in our model either glycolysis is not sufficient
to compensate for the impaired OXPHOS or other mechanisms
independent of a compromised electron transport chain, but ini-
tiated by mtDNA DSBs, are responsible for oligodendrocyte
death. In support of the latter hypothesis, it has been shown that
mtDNA, its fragments, and other mitochondrial components
(e.g., formyl peptides) act as nonmicrobial damage-associated
molecular patterns capable of activating innate immunity and
inflammation (Krysko et al., 2011) by binding to Toll-like recep-
tor 9 (TLR9; Zhang et al., 2010; Wei et al., 2015). Along this line,
it was recently shown that mtDNA released into the cytosol as a
consequence of mitochondrial stress can activate the stimulator
of interferon genes (STING) pathway and the production of cy-
tokines (Barber, 2015; West et al., 2015). Hence, it is plausible
that mtDNA fragments accumulated in the oligodendrocytes of
induced PLP:mtPstI mice could activate the TLR9 and/or STING
pathways and compromise oligodendrocyte survival.
Another possible mechanism of oligodendrocyte death is the
accumulation of reactive oxygen species (ROS). Increased ROS
production by mitochondrial oxidases and other cellular sources
is implicated in demyelination and neurodegeneration inMS and
EAE (Smith et al., 1999; van Horssen et al., 2008; Haider et al.,
2011; Fischer et al., 2012;Ohl et al., 2016). Since oligodendrocytes
are highly vulnerable to ROS-mediated death due to low levels of
cellular glutathione and high levels of iron, which catalyzes hy-
drogen peroxide conversion into hydroxyl radicals (McTigue and
Tripathi, 2008), it is believed that ROS are key contributors to
oligodendrocyte death and demyelination (McTigue and Tri-
pathi, 2008). ROS increase in dysfunctional mitochondria with
impaired electron transport, and susceptible cells (e.g., stem
cells) are especially sensitive to ROS generated bymtDNAmuta-
tions (Ha¨ma¨la¨inen et al., 2015) or DSBs (Pinto et al., 2017). On
this basis, it is reasonable to hypothesize that excessive ROS pro-
duction in PLP:mtPstI mice could lead to oligodendrocyte death
and demyelination.
We cannot exclude that toxic metabolites accumulating as a
result of mitochondrial dysfunction may cause axonal damage
independently of oligodendrocyte death. This idea is corrobo-
rated by thework ofViader et al. (2011, 2013), who demonstrated
that mitochondrial metabolism disruption by Tfam loss of func-
tion inmyelinating SCs causes the accumulation of toxic acylcar-
nitine lipid intermediates. These do not affect SC survival but
induce axonal damage that only at later stages leads to SC death
and demyelination as secondary consequence of the primary ax-
onopathy. It is plausible that in ourmodelmtDNADSBsmay cause
axonal damage not only secondary to oligodendrocyte death, but as
a primary event as well.
The consequence of oligodendrocyte death in PLP:mtPstI
mice is glial reactivity. Since this is typically associated with the
release of proinflammatory molecules such as cytokines and
chemokines (Pekny et al., 2016; Gualtierotti et al., 2017), we pre-
sume that it is the production of such mediators by reactive glia
that promotes the recruitment of immune cells into the CNS,
which we showed by histological analysis. To assess the type and
degree of activation of the adaptive immune response in our
model, we are now conducting a detailed cell profiling by flow
cytometry both in the CNS and in peripheral immune organs.
This is the focus of a separate comprehensive study.
Following just a brief period ofmtDNADSBs, we detected the
presence of myelin-specific antibodies. It should be noted that in
MS the pathogenic function of myelin-specific antibodies is con-
troversial. A number of early reports identified anti-MOG anti-
bodies in MS patients; however, the accuracy of the detection
methods has since been questioned. Recent studies found anti-
MOG antibodies to be transient and restricted to acute dissemi-
nated encephalomyelitis and pediatric MS (Ramanathan et al.,
2016). In our model, such antibodies are likely produced against
myelin antigens released from distressed oligodendrocytes, sup-
porting the idea of secondary adaptive immune activation in re-
sponse to a CNS-intrinsic trigger.
It has been suggested that mitochondrial dysfunction, in-
cluding mtDNA mutations, may alter the risk of the develop-
ment of various diseases, including MS (Hudson et al., 2014;
Keogh and Chinnery, 2015). Therefore, we devised a short pro-
tocol of mtDNA damage to test whether relatively mild mito-
chondrial distress, not sufficient to cause cell death or obvious
phenotypical alterations, could affect the response to neuroim-
mune disease. PLP:mtPstI mice with brief transient induction of
mtDNA DSBs showed expression of mtPstI, which caused low
levels ofmtDNAdeletions butwas not sufficient to causemtDNA
depletion, indicating that OXPHOS function was mostly intact.
Induced with EAE, PLP:mtPstI mice developed a more severe
chronic phenotype than control mice, suggesting that mildmito-
chondrial alterations, even if they are per se are nonpathogenic,
may exacerbate concomitant neurologic conditions or constitute
a predisposing factor.
In summary, our findings demonstrate that mtDNA DSBs
cause primary oligodendropathy, which triggers demyelination
and irreversible neurological deficit. This raises the possibility
that mtDNA damage or OXPHOS dysfunction in oligodendro-
cytes might play a pathogenic role in chronic demyelinating dis-
eases, possibly including certain forms of MS. We believe this
warrants an in-depth investigation of mitochondrial bioenerget-
ics in the oligodendrocytes of MS patients. Importantly, with the
PLP:mtPstI mouse model we now have a sophisticated in vivo
tool to address the dependence of oligodendrocytes on mito-
chondrial function. Indeed, to our knowledge, this is the only
model where the severity and timing of oligodendrocyte-specific
mtDNA damage can be controlled, allowing for modulation of
the degree of oligodendrocyte death, demyelination, and func-
tional impairment. Additionally, induced PLP:mtPstI mice reca-
pitulate the hallmarks of demyelinating syndromes associated
with neuronal degeneration more accurately than the models
currently available. This is especially relevant as the lack of appro-
priate preclinical models is widely regarded as one of the main
reasons for the failure of producing effective remyelinating ther-
apies for chronic demyelinating syndromes. We believe the PLP:
mtPstI mouse can fill this void and provide an ideal platform for
testing remyelinating and neuroprotective agents.
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